Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.
PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.
Encare was established in 2009 to implement the ERAS Protocols on a global basis by - providing training to health care professionals on the ERAS Protocols - providing an interactive and web-based information system for evidence based - best practice management (EBM) The company has developed an interactive, user-friendly interface for the collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence. The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings. Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States. The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery.
Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.
Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.
SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits. The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity.
Capitainer AB, based in Stockholm, Sweden, specializes in manufacturing innovative blood collection devices for micro sampling, allowing patients to collect their own volume-defined dried blood spots at home. Founded in 2016, Capitainer's technology offers a more accurate and convenient alternative to traditional blood sampling methods, significantly reducing the need for patients to travel for tests. By facilitating remote blood sample collection that can be sent to laboratories through regular mail, Capitainer enhances the efficiency of healthcare providers and contributes to cost and environmental savings associated with managing conventional blood samples.
Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.
PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.
Synartro is a Swedish research and development company focused on creating innovative treatments for osteoarthritis (OA) by utilizing patented drug delivery technology in conjunction with established medications. Its lead program, SYN321, features a novel therapy that combines diclofenac, a nonsteroidal anti-inflammatory drug, with hyaluronan to enhance pain relief for knee OA, a condition that affects many patients inadequately. Synartro aims to improve treatment efficacy through local injection methods that ensure sustained drug release while minimizing systemic side effects, thereby enabling clinicians to potentially slow or halt disease progression. The company is positioned to expand its offerings beyond knee OA, addressing a significant unmet need in the management of osteoarthritis.
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.
Cavis Technologies is an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.
Predicare AB, established in 2010 and based in Gothenburg, Sweden, specializes in developing decision support systems for the healthcare sector. Its primary product, the RETTS system, is designed to enhance emergency care by facilitating rapid triage and treatment through the assessment of vital parameters and the collection of structured medical histories. This clinical decision support tool aids healthcare professionals in making informed and timely decisions for a diverse range of patients, including adults, children, pregnant women, and those facing psychiatric emergencies. By streamlining the evaluation process, Predicare aims to improve the quality of care provided in emergency situations.
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.
SINGLE TECHNOLOGIES develops a new type of single-molecule-sensitive 3D sequencing system.They provide single-molecule detection, fiber optics, 3D imaging, genomics, sequencing, and 3-D Seq.
Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit.
Likvor has developed a unique instrument for measuring the cerebrospinal fluid (brain fluid) pressure and flow. Likvor AB is an Umeå based medical device company which has developed a system to be used in neurological investigations. Likvor CELDA System is the result of close to 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Likvor AB is marketing Likvor CELDA System and CELDA Tools. Likvor AB was established in 2007. Likvor AB first product Likvor CELDA System, was available to the market in 2009 when it was CE-marked. The company is certified according to ISO-13485. Likvor AB continues to develop new methods and devices in the area of CSF dynamics, together with the researchers at Umeå University and Umeå University Hospital.
Lipigon Pharmaceuticals AB is a biopharmaceutical company based in Umeå, Sweden, that specializes in the development of therapeutics for dyslipidemia and metabolic diseases. Founded in 2010, the company focuses on innovative treatments targeting lipoprotein lipase (LPL), an enzyme crucial for fat metabolism. Lipigon aims to address conditions related to low LPL activity, such as elevated blood fats, insulin resistance, and metabolic syndrome. The company's portfolio includes treatments for rare diseases like lipodystrophy and homozygous familial hypercholesterolemia, where existing therapies are insufficient. Lipigon has entered into a collaboration with AstraZeneca to further develop LPL-based pharmaceuticals, potentially receiving significant financial support as milestones in development and sales are achieved.
Cartana AB is a biotechnology company based in Solna, Sweden, specializing in mapping gene expression in brain tissue through In Situ Sequencing (ISS). Founded in 2017, Cartana's innovative technology allows for the simultaneous analysis of hundreds of genes within individual cells while preserving tissue morphology. This capability is essential for advancing research and biomarker discovery, treatment validation, and the development of future diagnostic tools. The company's flagship product, NeuroKit: Brain Cell Mapping, can identify over 100 genes in a single tissue section. Cartana also provides sequencing services that include sample preparation and analysis, facilitating deeper understanding of brain functions and diseases as well as tumors and other organs. As of August 2020, Cartana operates as a subsidiary of 10x Genomics, Inc.
Empe Diagnostics is committed to combat drug resistance in Tuberculosis (TB) and Sexually Transmitted Disease (STD), EMPE Diagnostics aims to develop simple and rapid diagnostic solutions for infectious diseases with a special focus on antimicrobial resistance.
The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.
Medpro Clinic Group is a healthcare business that operates six innovative care centers and provides care with a personal service and high standards. Medpro Clinic's operations are run by a dedicated staff who are passionate about care with high quality and preserved integrity. Medpro Clinic Group is headquartered in Sweden.
Liv Diagnostics AB, founded in 2016 and based in Mölndal, Sweden, specializes in developing diagnostic tools that analyze tumor cells to assess the risk of metastasis. The company's innovative approach focuses on direct analysis of cancer cell behavior, contrasting with traditional indirect diagnostic methods. By mimicking the natural environment of cells within the human body, Liv Diagnostics enables physicians to directly observe the behavior of living cancer cells. Their product, CellRACE, quantifies the migration capacity of these cells, providing critical predictive information about metastasis risk. Liv Diagnostics operates as a subsidiary of Cline Scientific AB.
Raytelligence AB, a subsidiary of Swedish Adrenaline founded in 2015, specializes in developing microwave sensors for the healthcare and industrial markets. The company focuses on vital sign monitoring, offering products such as the RayVS1 sensor, which is capable of monitoring heartbeat, movement, and body position. Raytelligence's innovative solutions include cloud-based signal processing and analysis services, facilitating home monitoring for users. The company has received recognition for its advancements, including a grant from the Swedish Innovation Bureau to support the development of its radar sensor technology. Since its inception, Raytelligence has successfully certified its sensor for home use and established partnerships for sensor development in various applications, including the road construction industry and e-Health initiatives. The team at Raytelligence combines expertise in industrial design and radar signal processing, positioning the company as a key player in the sensor technology sector.
1928 Diagnostics is a digital health company that specializes in bioinformatics, focusing on the analysis of genomic data to combat antibiotic resistance. The company provides a cloud-based platform designed to assist microbiologists in utilizing their sequencing data effectively. Its software service facilitates outbreak tracing and diagnostics, enabling healthcare providers to implement comprehensive infection control measures. By offering a user-friendly, fast, and secure service, 1928 Diagnostics supports customers across healthcare, food, and environmental sectors in tracking and minimizing the spread of bacteria, viruses, and fungi on a global scale.
MedFilm business idea is to convey information about surgical interventions to patients through animation and film. MedFilm, we help the health-care sector to communicate information about operations and treatments to patients simply and effectively. We provide 3D animated patient films in more than a dozen languages in order to improve patient understanding, confidence, and participation. The films are shown in hospitals around Scandinavia. Our film tablets provide information about each operation when the patient is admitted and when they wake up. The films are also shown on waiting room screens as well as online at patients’ homes.
The idea for PictureMyLife born out of a personal experience and a need that They have seen are the others - to make life easier, more inspiring and stimulating for children with impaired comprehension skills as well as their families and educators. Today, much of the communication of children in handwritten contact books and schedules that put together the parts that must first be printed and then cut and pasted in place. They want to help change Their digital platform. They are founders and working with PictureMyLife named Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren and Maria Skantz and They have many years of experience in communication and education in health care, health and social care.
Learning To Sleep offers clinically proven sleep improvement programs for people with sleep disorder through web and mobile devices. Their products has already helped over 40 000 people to live a better life and their unique business model establish also a strong relation between patients and their physicist.
Attana AB, founded in 2002 and based in Stockholm, Sweden, specializes in providing biologically relevant information that enhances the efficiency and performance of pharmaceutical drug development. The company develops third-generation analytical biosensor instruments that automate the analysis of molecular interactions with cells and tissues. These biosensors are utilized to determine binding characteristics, such as specificity, kinetics, and affinity of various biomolecules, including cells, antibodies, proteins, viruses, and bacteria. Attana serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical companies in Europe and Asia, and its technology has received validation from multiple reputable organizations in the field. The company also offers contract research services to further support the drug development process.